AUTHORS
Hong-Xiao Han, MD, Yu-han Gao, PhD2, Haoyi Xu3, Hong-yi Wang4, Yue Dang5, Zihan Yang6, Jian Li, MD7, Lu Zhang, M.D.8
AFFILIATIONS
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
4 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
8 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
ABSTRACT
Objectives: Hyaline-vascular (HV) type is the predominant pathology in unicentric Castleman disease (UCD), but can also be seen in idiopathic multicentric Castleman disease (iMCD). Current CDCN (Castleman Disease Collaborative Network) guidelines do not differentiate treatment by pathological subtype, so HV-iMCD is managed identically to plasmacytic/mixed (P/M)-iMCD. Whether this approach is appropriate remains uncertain. We therefore used a large retrospective cohort to determine whether HV-iMCD has distinct clinical and prognostic characteristics.
Methods: We reviewed records of 75 patients with HV-iMCD diagnosed at Peking Union Medical College Hospital from 2000 to 2026, and compared them with 443 P/M-iMCD, 253 HV-UCD, and 56 HV-type asymptomatic multicentric Castleman disease (HV-aMCD) patients.
Results: Of the 75 HV-iMCD patients, 41 were male and 34 female, median age 46 years (range, 16-81). Compared with P/M-iMCD, HV-iMCD had a higher proportion of TAFRO subtype (P<0.001), more frequent anasarca (P< 0.001), hepatosplenomegaly (P = 0.004), and renal insufficiency (P = 0.052), and lower platelet counts (P < 0.001). Inflammatory markers, including CRP, ESR, and interleukin-6, were significantly lower in HV-iMCD (all P < 0.001). Treatment choices for these patients did not differ between the two groups, consistent with current guidelines. After a median follow-up of 35 months (range, 1-287), HV-iMCD showed significantly worse overall survival (OS) than P/M-iMCD (3-year OS: 80.6% vs. 93.6%; 5-year OS: 78.4% vs. 91.5%; HR = 2.849, 95% CI: 1.547–5.248, P < 0.001). Compared with HV-UCD and HV-aMCD, HV-iMCD had more severe clinical manifestations and inflammatory responses, and its prognosis was significantly worse (P < 0.001).
Conclusions: HV-iMCD exhibits distinct clinical features and poorer prognosis than P/M-iMCD, challenging the current treatment algorithm which did not focus on pathological subtypes. Further studies are warranted to further validate this finding.
DISCLOSURES
Hong-Xiao Han, MD: No relevant conflicts of interest to declare.